NTRK1 and idiopathic pulmonary fibrosis: To determine the role of this kinase in CpG-induced myofibroblast differentiation, normal and IPF lung fibroblasts were activated with 10 μM of CpG and treated with 500 nM of Nu7441 (a specific DNA-PKcs small molecule inhibitor [16]) or 300 nM of BIBF-1120 (a multi-receptor tyrosine kinase inhibitor, also known as nintedanib and OFEV) for 24 h.